Evidence map›Paper›PMID 32886277›Full record

ArticleInternational journal of hematology2020

Complete metabolic remission in an 84-year old patient with relapsed/refractory diffuse large B-cell lymphoma following combination immunotherapy with lenalidomide plus rituximab.

Ciprian Tomuleasa, Sabina Iluta, Sergiu Pasca, Andrei Roman, Doina Piciu, Ciprian Jitaru, Patric Teodorescu, Ioana Rus, Anca Bojan, Delia Dima and 2 more

Abstract readCase ReportsLetter
PubMed Publisher
In one paragraph

Article in International journal of hematology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Ciprian TomuleasaDepartment of Hematology, Ion Chiricuta Clinical Cancer Center, Cluj-Napoca, Romania. ciprian.tomuleasa@umfcluj.ro.ORCID http://orcid.org/0000-0001-5500-1519
Sabina IlutaDepartment of Hematology, Ion Chiricuta Clinical Cancer Center, Cluj-Napoca, Romania.
Sergiu PascaDepartment of Hematology, Ion Chiricuta Clinical Cancer Center, Cluj-Napoca, Romania.
Andrei RomanDepartment of Radiology, Iuliu Hatieganu University of Medicine and Pharmacy Cluj Napoca, Cluj-Napoca, Romania.
Doina PiciuDepartment of Radiology, Iuliu Hatieganu University of Medicine and Pharmacy Cluj Napoca, Cluj-Napoca, Romania.
Ciprian JitaruDepartment of Hematology, Ion Chiricuta Clinical Cancer Center, Cluj-Napoca, Romania.
Patric TeodorescuDepartment of Hematology, Ion Chiricuta Clinical Cancer Center, Cluj-Napoca, Romania.
Ioana RusDepartment of Hematology, Ion Chiricuta Clinical Cancer Center, Cluj-Napoca, Romania.
Anca BojanDepartment of Hematology, Ion Chiricuta Clinical Cancer Center, Cluj-Napoca, Romania.
Delia DimaDepartment of Hematology, Ion Chiricuta Clinical Cancer Center, Cluj-Napoca, Romania.
Mihnea ZdrengheaDepartment of Hematology, Ion Chiricuta Clinical Cancer Center, Cluj-Napoca, Romania.
Bobe PetrushevMedfuture Research Center, Iuliu Hatieganu University of Medicine and Pharmacy Cluj Napoca, Cluj-Napoca, Romania.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Remission InductionAged, 80 and overAntineoplastic Combined Chemotherapy ProtocolsHumansImmunotherapyLenalidomideLymphoma, Large B-Cell, DiffuseMaleNeoplasm Recurrence, LocalPositron Emission Tomography Computed TomographyRituximabTreatment OutcomeLenalidomideRituximab

Identifiers

PMID32886277

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.